Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315)
Adel Mandl(Johns Hopkins University), Jan H. Beumer(Johns Hopkins University), Bhaumik B. Patel(Virginia Commonwealth University), Bhavana Konda(The Ohio State University), Anteneh Tesfaye(Georgetown University), Timothy F. Burns(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Stephen V. Liu(Georgetown University), Kristen K. Ciombor(Vanderbilt University Medical Center), Heloisa P. Soares(University of Utah), James Ohr(University of Pittsburgh), Lakshmana Das(All India Institute of Medical Sciences Rishikesh), D Li(City Of Hope National Medical Center), Ruizhe Chen(Johns Hopkins University), Tanya B. Dorff(City Of Hope National Medical Center), Kang Chen(Lanzhou University Second Hospital), Anup Kumar Kasi(The University of Kansas Cancer Center), Jonathan R Strosberg(Moffitt Cancer Center), Aman Chauhan(Sylvester Comprehensive Cancer Center), Farshid Dayyani(University of California, Irvine Medical Center), Michael A Carducci(Johns Hopkins University), V. Sukrithan(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 0
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|998
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|846